Levocin Injection (Levofloxacin Hydrate)

Adult administration

Administer by slow intravenous infusion 1 to 2 times a day. The dosage is determined based on the type of infection and its severity, as well as the susceptibility of the suspected causative bacteria. The duration of treatment varies depending on the extent of the disease's progression; however, administration should continue for at least 48 to 72 hours after a state of defervescence or evidence of sterilization is obtained. The method of administration is slow intravenous infusion once or twice a day, for a maximum of 14 days, with a minimum infusion time of

This medication is used as a fluoroquinolone antibiotic for the treatment of bacterial infections. It may cause tendon-related conditions such as tendinitis or tendon rupture, particularly affecting the Achilles tendon, so caution is advised. If peripheral neuropathy or central nervous system symptoms such as sensory abnormalities, headache, dizziness, seizures occur, usage should be immediately discontinued. This medication should not be administered to patients with myasthenia gravis as it may exacerbate symptoms. The medication should be administered slowly via intravenous injection, and if there is a sudden drop in blood pressure, it should be discontinued immediately. When used in conjunction with corticosteroids, the risk of tendon damage increases, so it is best to avoid combined use. This medication should not be given to adolescents under 18 years of age and to women who are pregnant or breastfeeding. Caution should be exercised when administering to patients with a history of seizures or central nervous system disorders as it may increase the risk of seizures. During treatment with this medication, exposure to sunlight or UV rays should be avoided, and if photosensitivity reactions occur, administration should be stopped immediately. Diabetes patients needing blood sugar control should carefully monitor blood sugar changes while taking this medication, and if hypoglycemic symptoms occur, immediate treatment should be sought. Patients with heart disease may experience serious side effects such as aortic aneurysm, aortic dissection, and cardiac valve regurgitation, requiring special caution. In cases of overdose, central nervous system symptoms and cardiac abnormalities may occur, so immediate medical attention is necessary. This medication can interact with other drugs, so inform healthcare providers of any other medications being taken. Caution should be exercised as dizziness or drowsiness may occur when driving or operating machinery. It is advisable to administer this medication only after accurate diagnosis and susceptibility testing of the infection site, and only for the minimum required duration.

Serious side effects

Hives, angioedema (swelling of the tongue, larynx, throat, facial swelling, etc.), chest tightness, difficulty breathing, cold sweat, pallor, severe allergic reactions, severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS)), asthma attacks, respiratory abnormalities accompanied by coughing and fever, shortness of breath, jaundice (yellowing of skin or eyes), extreme malaise, liver abnormalities (jaundice), sudden and severe

Mild side effects

• Itching
• rash
• nausea
• diarrhea
• loss of appetite
• vomiting
• abdominal pain
• indigestion
• abdominal bloating
• constipation

This medication should be stored in a sealed container to protect it from air and light. It is best to keep it away from direct sunlight and in a dark place. Additionally, the storage temperature should be maintained at room temperature between 1 degree Celsius and 30 degrees Celsius.

Appearance

A clear, yellow solution with a light green tint filled in a colorless, transparent plastic container for intravenous use.

Package unit

100 milliliters/pack, 150 milliliters/pack